Business Context and Reporting Period
Company: Amarin Corporation plc (AMRN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Amarin is a pharmaceutical company focused on cardiovascular health, primarily commercializing VASCEPA (icosapent ethyl) in the U.S. and VAZKEPA in Europe and other international markets. The product is indicated for reducing triglyceride levels and reducing cardiovascular risk in high-risk patients.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue, Net | $228.6 million | $306.9 million | (26%) |
| Product Revenue, Net | $204.6 million | $285.3 million | (28%) |
| Licensing & Royalty Revenue | $24.0 million | $21.6 million | +11% |
| Cost of Goods Sold (Total) | $147.2 million | $141.4 million | +4% |
| Gross Margin | $81.4 million (28%) | $165.5 million (50%) | Significant Decline |
| Operating Loss | $(91.8) million | $(67.6) million | Widened |
| Net Loss | $(82.2) million | $(59.1) million | Widened |
| Cash & Cash Equivalents | $121.0 million | $199.3 million | (39%) |
| Short-Term Investments | $173.2 million | $121.4 million | +43% |
| Total Liquidity | $294.2 million | $320.7 million | (8%) |
| Debt | $0 | $0 | N/A |
Note: Gross margin decline is primarily driven by $36.5 million in restructuring inventory charges and $8.0 million in inventory write-offs in 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 26% year-over-year. U.S. product revenue fell 39% to $166.7 million due to generic competition, a decrease in net selling price, and the loss of a large national Pharmacy Benefit Manager (PBM) which stopped covering VASCEPA as an exclusive product. Conversely, non-U.S. product revenue increased 200% to $37.9 million, driven by sales to international partners.
- Margin Compression: Reported gross margin dropped from 50% in 2023 to 28% in 2024. Excluding restructuring inventory charges ($36.5M) and inventory write-offs ($8.0M), the adjusted gross margin was 50%.
- Cost Reductions: Selling, General, and Administrative (SG&A) expenses decreased 24% to $152.3 million, reflecting the impact of the Organizational Restructuring Program (ORP) implemented in 2023, which eliminated the U.S. sales force and reduced the workforce by approximately 30%.
- Licensing Milestones: Licensing revenue increased due to a $15.0 million milestone payment from the NMPA approval of VASCEPA in China under the REDUCE-IT indication and a $1.2 million milestone from the PBS listing in Australia.
Guidance, Outlook, and Risks
- Guidance: The Company has suspended providing net revenue guidance due to the inherent uncertainty of the European launch and the impact of U.S. generic competition.
- Management Commentary: Management remains focused on advancing pricing and reimbursement activities in Europe and maintaining market leadership in the U.S. despite generic competition. The company expects to continue incurring operating losses for an indefinite period.
- Key Risks:
- Generic Competition: Multiple generic versions of icosapent ethyl are available in the U.S., significantly impacting market share (dropped to ~53% in 2024) and pricing power.
- European Commercialization: Success depends on securing favorable pricing and reimbursement in individual EU countries, which is unpredictable and time-consuming.
- Litigation: The Company faces multiple antitrust lawsuits from generic competitors (Dr. Reddy's, Hikma, Teva, Apotex) alleging anticompetitive practices regarding API supply. Additionally, a securities class action was dismissed without prejudice but plaintiffs were granted time to amend.
- Stock Listing: The Company received a deficiency notice from NASDAQ for trading below the $1.00 minimum bid price. It was granted an extension until May 19, 2025, to regain compliance.
- Unusual Items: Significant non-cash and cash restructuring charges related to inventory ($36.5 million) and inventory write-offs ($8.0 million) impacted the bottom line. The Company also announced a 1-for-20 reverse stock split (ADS ratio change) effective April 2025 to address listing requirements.
Investor Verification Checklist
- European Reimbursement Status: Verify the specific countries where national reimbursement has been secured versus those still negotiating, as this drives non-U.S. revenue growth.
- Generic Market Share: Monitor Symphony Health data for VASCEPA branded prescription trends versus generic icosapent ethyl prescriptions to assess the severity of U.S. market erosion.
- Antitrust Litigation Progress: Track the status of the antitrust lawsuits filed by generic manufacturers regarding API supply constraints.
- NASDAQ Compliance: Confirm the stock price trajectory relative to the $1.00 minimum bid requirement and the effectiveness of the upcoming reverse stock split.
- Liquidity Runway: Assess the $294.2 million cash position against projected burn rates, considering the suspension of revenue guidance and ongoing restructuring costs.